...Jingru Ren; Jianchun Wang; Ran Liu; Yunyi Jin; Jing Guo; Yan Yao; Jingjing Luo; Hongjun Hao; Feng Gao Introduction: Rituximab is a monoclonal chimeric antibody against CD20 + B cells. We aimed to assess the long-term efficacy and safety of CD20 + B cell-guided treatment with low-dose rituximab...

... and safety of MVD in elderly patients. Many neurosurgeons fear complications and concerns over fitness for surgery. Although there are some studies on the safety and efficacy of MVD in elderly patients with trigeminal neuralgia [ 10,11,12 ], little is known about the clinical value of MVD in elderly patients...

...Claudio Gobbi; Chiara Zecca; Michael Linnebank; Stefanie Müller; Xiaojun You; Rosetta Meier; Emmanuela Borter; Martin Traber Background: There is a scarcity of reports comparing efficacy and tolerability of the multiple sclerosis (MS) disease-modifying therapies [DMTs; intramuscular interferon-β1a...

...Alison J. Pilgrim The efficacy of the 5-HT 1 receptor agonist sumatriptan in the acute treatment of migraine has been investigated in an extensive programme of controlled clinical trials. Sumatriptan provided rapid relief from migraine headache with onset of relief occurring within 10 min of a 6 mg...

... and the other with placebo. Efficacy assessments were recorded on standard diary cards completed by each patient. A primary response was defined as the complete absence of headache pain in the 24 hour period following administration of the first dose of study medication. Safety assessments included ECGs...

...Michel D. Ferrari Efficacy with currently marketed antimigraine compounds is less than optimal. 311C90 is a novel and selective 5-HT 1D receptor agonist in development for the acute treatment of migraine. It shows evidence of both central and peripheral activity within the trigemino-vascular system...

...Gilles E.A. Geraud 311C90 is an orally active 5-HT ID agonist with both central and peripheral actions that is currently being developed as an acute antimigraine treatment. Several studies have demonstrated the safety and efficacy of 311C90 in the treatment of a single migraine headache.The...

..., instructions or products referred to in the content or advertisements. 311C90 Receptor specificity Vasoconstriction Antiemetic effects Trigemino-vascular system Clinical pharmacology Efficacy Safety Quality of life 25 2 2008 ...

...John G. Edmeads 25 2 2008 311C90 Trigemino-vascular system Efficacy Safety 1996 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means...

...%. Almotriptan is associated with a rapid onset of action, with 30-min pain-relief and pain-free rates significantly better than placebo (p < 0.05). Direct comparator studies show the efficacy of almotriptan 12.5 mg to be comparable to that of sumatriptan but almotriptan is associated with superior...

... of this study was based on the co-primary efficacy hypotheses that patients would (i) demonstrate a greater preference for the rizatriptan tablet versus ergotamine/caffeine tablets or (ii) rizatriptan would be superior to ergotamine/caffeine in the proportion of patients pain free at 2 h. A total of 372...

...Hans-Christoph Diener; Jan-Peter Jansen; Avinoan Reches; Julio Pascual; Daniela Pitei; Timothy J. Steiner The 5-HT 1B/1D/1F agonist eletriptan, at an oral dose of 80 mg, has been shown to be more efficacious than sumatriptan 100 mg and placebo in the treatment of migraine attacks with or without...

...Y. Langan; J.S. Duncan; J.W.A.S. Sander A retrospective audit of the perceived efficacy and tolerability of adjunctive gabapentin (GBT) therapy in patients with intractable epilepsy was carried out. The case-notes of 263 consecutive patients attending a tertiary referral centre in whom GBT had been...